A Case of Adenocarcinoma of the Lung which Was Successfully Treated by Chemotherapy with Patient Survival without Recurrence for More Than Three Years
Akiba, Tadashi; Saijo, Nagahiro; Miyamoto, Kengo; Sakurai, Masanori; Tamura, Tomohide; Sasaki, Yasutsuna; Eguchi, Kenji; Shinkai, Tetsu; Uei, Yoshio; Fujiwara, Yasuhiro; Nakano, Hidehiko; Nakagawa, Kazuhiko; Hong, Weon Seon; Akiba Tadashi; Department of Internal Medicine, National Cancer Center Hospital; Saijo Nagahiro; Department of Internal Medicine, National Cancer Center Hospital; Miyamoto Kengo; Department of Internal Medicine, National Cancer Center Hospital; Sakurai Masanori; Department of Internal Medicine, National Cancer Center Hospital; Tamura Tomohide; Department of Internal Medicine, National Cancer Center Hospital; Sasaki Yasutsuna; Department of Internal Medicine, National Cancer Center Hospital; Eguchi Kenji; Department of Internal Medicine, National Cancer Center Hospital; Shinkai Tetsu; Department of Internal Medicine, National Cancer Center Hospital; Uei Yoshio; Clinical Laboratory, National Cancer Center Hospital; Fujiwara Yasuhiro; Pharmacology Division, National Cancer Center Research Institute; Nakano Hidehiko; Pharmacology Division, National Cancer Center Research Institute; Nakagawa Kazuhiko; Pharmacology Division, National Cancer Center Research Institute; Hong Weon Seon; Pharmacology Division, National Cancer Center Research Institute
Журнал:
Japanese Journal of Clinical Oncology
Дата:
1987
Аннотация:
A 63-year-old man was admitted to the National Cancer Center Hospital on December 20, 1983 for a close examination of the abnormal shadows found in chest roentgenograms. Chest radiographs showed a massive right pleural effusion, a large tumor in the right bilar region and swelling of the left hilar nodes. Transcutaneous needle biopsy revealed the tumor's cytological type to be adenocarcinoma. The clinical stage was considered to be T3N2M1 (American joint committee (AJC) stage III M1), and his performance status was 4, so he was given etoposide (VP-16) alone as the initial chemotherapy treatment. He showed a partial response upon two courses of VP-16 therapy. Subsequently, one course of cisplatin (80 mg/m<sup>2</sup>) + vindesine (3.3 mg/m<sup>2</sup>), two courses of VP-16 (80 mg/m<sup>2</sup> D1–4), five courses of cyclophosphamide (80 mg/m<sup>2</sup>) + adriamycin (50 mg/m<sup>2</sup>) + vincristine (1.4 mg/m<sup>2</sup>) and two courses of VP-16 (100 mg/m<sup>2</sup> D1, 3, 5) were administered sequentially until May 31, 1985. No radiation therapy was given and, up to March 31, 1987, no sign of recurrence had been observed.
3.811Мб